HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target
Benzinga Newsdesk 9 months ago
NewsUpgradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.
HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.